During the last three months, 8 analysts shared their evaluations of Ventas (NYSE:VTR), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 4 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 2 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 1 | 1 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $75.25, a high estimate of $80.00, and a low estimate of $72.00. This current average has increased by 3.62% from the previous average price target of $72.62.
Decoding Analyst Ratings: A Detailed Look
The perception of Ventas by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Steve Sakwa | Evercore ISI Group | Raises | Outperform | $80.00 | $77.00 |
| Nicholas Yulico | Scotiabank | Raises | Sector Perform | $74.00 | $72.00 |
| Michael Mueller | JP Morgan | Raises | Overweight | $76.00 | $72.00 |
| Marie Ferguson | Argus Research | Maintains | Buy | $75.00 | $75.00 |
| Jonathan Hughes | Raymond James | Raises | Outperform | $78.00 | $74.00 |
| Richard Hill | Morgan Stanley | Raises | Equal-Weight | $75.00 | $70.00 |
| Nicholas Yulico | Scotiabank | Raises | Sector Perform | $72.00 | $71.00 |
| Michael Mueller | JP Morgan | Raises | Overweight | $72.00 | $70.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ventas. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ventas compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Ventas's stock. This comparison reveals trends in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Ventas's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Ventas analyst ratings.
Get to Know Ventas Better
Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
Ventas: Delving into Financials
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Ventas's revenue growth over a period of 3M has been noteworthy. As of 30 June, 2025, the company achieved a revenue growth rate of approximately 18.31%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 4.8%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Ventas's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 0.59%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Ventas's ROA stands out, surpassing industry averages. With an impressive ROA of 0.26%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Ventas's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.15.
What Are Analyst Ratings?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
